
What Wyden’s 2027 PBM Agenda Could Mean for Independent Pharmacies
The incoming Senate Finance majority can put PBMs back in the spotlight as Medicare develops new standards for pharmacy network contracts.
For an independent pharmacy, a Medicare Part D contract can determine whether the business can continue to serve patients who have filled their prescriptions there for years. The pharmacy may be eligible to join a network and still face a difficult decision about whether it can afford to dispense under the terms offered. That distinction should be at the center of the pharmacy benefit manager (PBM) debate when the new Congress convenes in January.
On November 4, following the midterm elections, Senator Ron Wyden (D, Oregon) outlined his agenda for the incoming Senate Finance Committee majority. He pledged to lower health care costs, challenge what he called the “corporate chokehold” on American health care, and press insurers and drugmakers to account for their practices.1
“Trump and Republicans have been running a smash-and-grab job on the American people,” he said. “Under my leadership, the top priorities of the Finance Committee will be affordability for us, accountability for them.”
Earlier in 2026, Wyden had singled out PBMs in a Finance Committee hearing on health care consolidation.2 The first opportunity to see what his agenda could mean for pharmacies comes from a law Congress already passed and the work federal regulators are doing to implement it.
READ MORE:
Medicare’s Pharmacy Contracting Rules Are the First Test
Sections 6223 and 6224 of the Consolidated Appropriations Act of 2026 address different parts of the Part D market. Section 6223 deals with the terms under which pharmacies can participate in plan networks. Section 6224 deals with how PBMs and their affiliates are compensated and what they must disclose. Both build on bipartisan work from Wyden and Senator Mike Crapo (R, Idaho), whose 2025 PBM bill also proposed changes to Medicaid spread pricing.3,4
Part D’s any-willing-pharmacy provision requires plan sponsors to allow pharmacies that meet the plan’s standard contract terms to join its network. Under 6223, those terms must meet federal standards for relevance and reasonableness beginning with the 2029 plan year. Congress directed the Department of Health and Human Services (HHS) to establish those standards by the first Monday in April 2028.3,5 That gives the incoming Finance Committee a concrete oversight question in 2027: How will regulators determine whether the terms a plan offers actually allow pharmacies to serve its members?
The Centers for Medicare & Medicaid Services (CMS) is already asking questions that go to the heart of that issue. Its September request for information (RFI) asks whether reimbursement and dispensing fees cover drug acquisition and operating costs, how payments change after claims are adjudicated, and whether CMS should establish reimbursement methods or rates as part of the contracting standards. It also asks whether the payment shown when a claim is processed reliably predicts what the pharmacy ultimately receives after reconciliation.5 For a pharmacy deciding whether to sign a contract, that last question is especially important. The number that appears when the prescription is filled may tell the owner relatively little about the economics of the contract over a full year.
CMS is moving on a separate track, however, under 6224. Its October proposed rule would implement limits on what PBMs and their affiliates can receive for services involving Part D drugs, including restrictions on compensation tied with drug prices. It also addresses reporting with plan sponsors and CMS, transparency around price guarantees, and disclosure of terms in certain agreements with manufacturers.3,6 A plan sponsor’s improved visibility into what it pays its PBM can help it evaluate that relationship. The terms offered to the dispensing pharmacy remain a separate issue, and that is where the 6223 standards could have their most direct effect.
Where Wyden Could Go Further in 2027
Wyden’s June drug-pricing RFI offers a preview of what additional legislation could address. It asks whether Medicare should establish minimum Part D dispensing fees and whether those fees should vary by pharmacy type, including retail, specialty, mail order and long-term care. A dispensing fee set with reliable cost data could make one part of pharmacy payment more predictable. Its practical value would still depend on how the contract reimburses the drug itself and how the plan or its PBM reconciles payments after dispensing.7
The same request asks how Medicare should account for margins earned within vertically integrated companies when evaluating Part D bids. It also raises 2 options for PBM-owned private-label products: disclosing the difference between what the private labeler pays to acquire the drug and what the PBM charges its clients, or conditioning dispensing of those products in Part D on compliance with a cost-plus pricing standard.7
READ MORE:
These questions matter because a corporate group can earn money at several points in the same prescription transaction. A limit on what the PBM can charge for administering a benefit addresses one source of revenue. Congress may also want to know how formulary decisions affect the revenue of an affiliated pharmacy or private-label company.
Wyden’s July health coverage RFI goes even further into corporate structure. It asks how regulators could better track ownership and financial relationships and whether benchmarking payments to affiliates could help protect unaffiliated providers. It also invites comment on the Warren-Hawley–sponsored “Break Up Big Medicine Act,” S. 3822, which would restrict common ownership across specified parts of the health care industry.8,9 That bill gives Congress a structural option to debate. The next step to watch is whether Wyden’s committee turns the ideas from the 2 RFIs into bill text or uses its hearings to build a record on particular contracting practices.
What Pharmacies Can Bring to the Debate
Congressional oversight could examine how network terms, reimbursement, and pharmacy choice work in practice. Useful questions include whether a plan’s specialty network requirements are tied with the services a pharmacy must provide, whether comparable pharmacies face comparable terms, and what patients experience when they have to move a prescription to another pharmacy. Those questions can also help policymakers distinguish legitimate differences in service and cost from practices that warrant closer scrutiny.
Independent pharmacies can contribute evidence drawn from ordinary operations. A set of de-identified claims that pairs acquisition invoices with adjudicated payments and subsequent adjustments can show how much the pharmacy actually received. Records of contract offers and amendments can show when reimbursement terms changed and whether the pharmacy could reasonably project their effect. Examples of delayed fills or transfers can connect those terms with what patients experience. The September CMS request specifically seeks information on acquisition and dispensing costs, payment reconciliation, and the predictability of final reimbursement.5
As of November 17, CMS had set a November 23 comment deadline for its pharmacy contracting request and a December 15 deadline for its PBM accountability proposed rule.5,6 Both records will remain relevant in 2027 as the committee evaluates the reach of the law it helped write. Wyden’s new majority can press for answers about how money moves within integrated companies and whether independent pharmacies can compete for the same patients. The measure of progress will be whether a Medicare beneficiary can keep using a pharmacy that can serve them on financially sustainable terms.
READ MORE:
REFERENCES
1. Wyden statement on Finance Committee democratic majority agenda. US Senate Committee on Finance. November 4, 2026. Accessed November 18, 2026. https://www.finance.senate.gov/ranking-members-news/wyden-statement-on-finance-committee-democratic-majority-agenda/
2. Wyden statement at Finance Committee hearing on corporatization and consolidation in health care. US Senate Committee on Finance. June 8, 2023. Accessed November 18, 2026. https://www.finance.senate.gov/chairmans-news/wyden-statement-at-finance-committee-hearing-on-corporatization-and-consolidation-in-health-care
3. Consolidated Appropriations Act, 2026, pub L no. 119-75, §§6223-6224. GovInfo. February 3, 2026. Accessed November 18, 2026. https://www.govinfo.gov/content/pkg/PLAW-119publ75/html/PLAW-119publ75.htm
4. S. 3345 (IS) - PBM Price Transparency and Accountability Act. GovInfo. December 4, 2025. Accessed November 18, 2026. https://www.govinfo.gov/app/details/BILLS-119s3345is
5. Request for information; Medicare Part D reasonable and relevant pharmacy contracting standards. Federal Register. September 24, 2026. Accessed November 18, 2026. https://www.federalregister.gov/d/2026-19535
6. Medicare program; implementation of sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026. Federal Register. October 20, 2026. Accessed November 18, 2026. https://www.federalregister.gov/documents/2026/10/20/2026-21420/medicare-program-implementation-of-sections-6219-6220-and-6224-of-the-consolidated-appropriations
7. Request for information: commonsense policy options to lower drug prices for patients. US Senate Committee on Finance, Minority Staff. June 16, 2026. Accessed November 18, 2026. https://www.finance.senate.gov/imo/media/doc/061626_sfc_drug_pricing_rfi.pdf
8. Health coverage that works for everyone: request for information. US Senate Committee on Finance, Minority Staff. July 30, 2026. Accessed November 18, 2026. https://www.finance.senate.gov/imo/media/doc/073026_sfc_health_coverage_rfi.pdf
9. S. 3822 (IS) - Break Up Big Medicine Act. GovInfo. February 10, 2026. Accessed November 18, 2026. https://www.govinfo.gov/app/details/BILLS-119s3822is
Related to this article








